Patents by Inventor Daniel Chuen-Fong Chan

Daniel Chuen-Fong Chan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Heterocyclic hydroxamic acids as protein deacetylase inhibitors and dual protein deacetylase-protein kinase inhibitors and methods of use thereof
    Patent number: 10508122
    Abstract: The present invention relates to novel hydroxamic acids which are specific histone deacetylase (HDAC) inhibitors and/or TTK/Mps1 kinase inhibitors, including pharmaceutically acceptable salts thereof, which are useful for modulating HDAC and/or TTK/Mps1 kinase activity, pharmaceutical compositions comprising these compounds, and processes for their preparation.
    Type: Grant
    Filed: July 19, 2017
    Date of Patent: December 17, 2019
    Assignee: The Regents of the University of Colorado, A Body Corporate
    Inventors: Xuedong Liu, Gan Zhang, Daniel Chuen-Fong Chan, Anthony D. Piscopio
  • Heterocyclic Hydroxamic Acids as Protein Deacetylase Inhibitors and Dual Protein Deacetylase-Protein Kinase Inhibitors and Methods of Use Thereof
    Publication number: 20180044352
    Abstract: The present invention relates to novel hydroxamic acids which are specific histone deacetylase (HDAC) inhibitors and/or TTK/Mps1 kinase inhibitors, including pharmaceutically acceptable salts thereof, which are useful for modulating HDAC and/or TTK/Mps1 kinase activity, pharmaceutical compositions comprising these compounds, and processes for their preparation.
    Type: Application
    Filed: July 19, 2017
    Publication date: February 15, 2018
    Applicant: The Regents of the University of Colorado, A Body Corporate
    Inventors: Xuedong Liu, Gan Zhang, Daniel Chuen-Fong Chan, Anthony D. Piscopio
  • Heterocyclic hydroxamic acids as protein deacetylase inhibitors and dual protein deacetylase-protein kinase inhibitors and methods of use thereof
    Patent number: 9840520
    Abstract: The present invention relates to novel hydroxamic acids which are specific histone deacetylase (HDAC) inhibitors and/or TTK/Mps1 kinase inhibitors, including pharmaceutically acceptable salts thereof, which are useful for modulating HDAC and/or TTK/Mps1 kinase activity, pharmaceutical compositions comprising these compounds, and processes for their preparation.
    Type: Grant
    Filed: May 14, 2015
    Date of Patent: December 12, 2017
    Assignee: The Regents of the University of Colorado, A Body Corporate
    Inventors: Xuedong Liu, Gan Zhang, Daniel Chuen-Fong Chan, Anthony D. Piscopio
  • Heterocyclic Hydroxamic Acids as Protein Deacetylase Inhibitors and Dual Protein Deacetylase-Protein Kinase Inhibitors and Methods of Use Thereof
    Publication number: 20170081343
    Abstract: The present invention relates to novel hydroxamic acids which are specific histone deacetylase (HDAC) inhibitors and/or TTK/Mps1 kinase inhibitors, including pharmaceutically acceptable salts thereof, which are useful for modulating HDAC and/or TTK/Mps1 kinase activity, pharmaceutical compositions comprising these compounds, and processes for their preparation.
    Type: Application
    Filed: May 14, 2015
    Publication date: March 23, 2017
    Applicant: The Regents of the University of Colorado, A Body Corporate
    Inventors: Xuedong Liu, Gan Zhang, Daniel Chuen-Fong Chan, Anthony D. Piscopio
  • Histone Deacetylase Inhibitors Sensitize Cancer Cells to Epidermal Growth Factor Inhibitors
    Publication number: 20080234265
    Abstract: Disclosed is the use of a combination of histone deacetylase inhibitors and epidermal growth factor receptor (EGFR) inhibitors to treat cancer.
    Type: Application
    Filed: March 13, 2006
    Publication date: September 25, 2008
    Applicant: THE REGENTS OF THE UNIVERSITY OF COLORADO
    Inventors: Samir E. Witta, Paul A. Bunn, Harry A. Drabkin, Robert M. Gemmill, Daniel Chuen-Fong Chan
  • HISTONE DEACETYLASE INHIBITORS SENSITIZE CANCER CELLS TO EPIDERMAL GROWTH FACTOR INHIBITORS
    Publication number: 20080182865
    Abstract: Disclosed is the use of a combination of histone deacetylase inhibitors and kinase inhibitors with anti-EGFR activity.
    Type: Application
    Filed: September 25, 2007
    Publication date: July 31, 2008
    Inventors: Samir E. Witta, Paul A. Bunn, Harry A. Drabkin, Robert M. Gemmill, Daniel Chuen-Fong Chan
  • Heterocyclic hydroxamic acids as protein deacetylase inhibitors and dual protein deacetylase-protein kinase inhibitors and methods of use thereof
    Patent number: RE47690
    Abstract: The present invention relates to novel hydroxamic acids which are specific histone deacetylase (HDAC) inhibitors and/or TTK/Mps1 kinase inhibitors, including pharmaceutically acceptable salts thereof, which are useful for modulating HDAC and/or TTK/Mps1 kinase activity, pharmaceutical compositions comprising these compounds, and processes for their preparation.
    Type: Grant
    Filed: May 1, 2018
    Date of Patent: November 5, 2019
    Assignee: The Regents of the University of Colorado, A Body Corporate
    Inventors: Xuedong Liu, Gan Zhang, Daniel Chuen-Fong Chan, Anthony D. Piscopio